Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial.

Bruce E StroberYayoi TadaUlrich MrowietzMark LebwohlPeter FoleyRichard G LangleyRichard Bruce WarrenMaggie WangVeerle VanvoordenBalint SzilagyiValerie CiaravinoCarle F Paul

Published in: The British journal of dermatology (2023)

High levels of clinical response were maintained through to three years of bimekizumab treatment in the vast majority of Week 16 responders. Long-term treatment with bimekizumab was efficacious, with important benefits on health-related quality of life (HRQoL), in patients with moderate to severe plaque psoriasis.

Keyphrases

clinical trial
coronary artery disease
early onset
phase iii
squamous cell carcinoma
combination therapy
rectal cancer
drug induced
replacement therapy